UCB Wins Two Key US Approvals: Bimzelx In Psoriasis, Zilbrysq In gMG
Launches To Follow In A Month, Late 2023
Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.
